Tech based research platform for Proprietary investments. We are floating around AI tools.

Joined April 2026
2 Photos and videos
AI infrastructure spending is accelerating toward ~$700bn annually, but the market has largely rewarded the obvious beneficiaries already. So we asked a different question: Which company has the potential to become the next Micron-style winner over the next phase of the AI buildout? Using our proprietary Birch Quotient and Birch Future Score to measure both a company’s current business strength and its potential to benefit from future AI-driven growth, we evaluated 20 companies last month across compute, memory, connectivity, power ICs and power infrastructure. The most interesting outcome? The highest future scores weren’t concentrated in GPUs. They emerged in the connectivity and power-delivery layers where product moats, design-ins and secular demand intersect. Our latest thematic deep dive: “The Grid Beneath the Boom: Hunting the Next Micron” 🔗 Link below- birchtree.ai/view/qkmyvhgx1o… #Micron
3
10
1,439
India’s diagnostics opportunity is large. But public-market access to it has been surprisingly scarce. 🧪 Our latest proprietary note explores Q-Line Biotech — potentially the first listed pure-play way to participate in India’s IVD localisation theme, in a market where most established leaders still remain private. A few things that stood out while researching: • India’s IVD market could grow to ~$3B by 2030 • Q-Line operates an annuity-style diagnostics model driven by recurring reagents • EBITDA margins expanded from 18% → 27.6% in under 3 years • Capacity already exists for multiple years of growth without major capex The interesting part is not just growth — but scarcity. Sometimes the market rerates the only listed door into a structural theme. We break down the business model, runway, scenario framework, key risks and why we believe this could become an interesting long-duration healthcare manufacturing story to track. Full deck below 👇 birchtree.ai/view/sq2hwxsuuf…
2
7
1,013
What a historic day for Indian Pharma!
Excellent results by wockhardt, our internal note- birchtree.ai/view/dgko6yy9nh…
1
8
731
India’s next consumption story may not start in Mumbai or Bengaluru anymore… it could start with a ₹99 pizza in Lucknow, a McCafé in Surat, or a KFC bucket in Patna. 🍕☕ Our latest proprietary report “First Bite” dives into how India’s next 300M consumers are reshaping the QSR casual dining landscape. Some key takeaways: • Tier 2/3 fast-food spending up 108% in just 2 years • Gen Z already drives ~40% of consumption • Organized QSR market projected to touch $47B by 2031 • Digital ordering, premiumisation & café culture are changing the game From Domino’s, McDonald’s & KFC to Barbeque Nation, Costa & Barista — we map the winners, turnarounds, and emerging themes across India’s food consumption boom. The “first bite” may look small today, but structurally, it could become one of India’s largest aspirational spending stories over the next decade. Read the full deck below 👇 birchtree.ai/view/a8far83t1n…
1
9
443
Excellent numbers by Venus Remedies.
Is this the mini wockhardt, part of our portfolio and our internal note- birchtree.ai/view-doc/xllrvn… #VenusRemedies
6
817
Interesting acquisition by Anupam Rasayan and 2 now in a short time frame, Bliss scale up can be great for both companies- birchtree.ai/view/ph3gy2twcb…
1
7
407
India’s API renaissance may just be beginning. A structural China 1 reset, Biosecure Act tailwinds, patent cliffs worth $200B , and a new generation of Indian CDMO/API champions are reshaping global pharma supply chains. In our latest AI aided proprietary sector report, we profile 25 Indian API players — from Divi’s & Laurus to Shilpa, Neuland, Acutaas and beyond. Key themes: • 190 blockbuster patent expiries by 2030 • $25-40B India capture opportunity • 50% jump in RFQs post Biosecure Act • Why CDMO specialty APIs could outperform generic pharma Full report below- birchtree.ai/view/ibvbkpusbq… #India #Pharma #API #CDMO #ChinaPlusOne #Healthcare #Investing #Biotech
3
12
2,593
Selling shares to retail in the garb of education is the biggest sin in financial services. All of us posting online have to be even more careful in making sure no stock is promoted as a must or guaranteed buy.
SEBI cracks down on an alleged finfluencer-led stock manipulation network using social media hype to pump SME stocks. @nizzgeneration
7
714
Trying to understand the Kirloskar group as an investor feels a bit like watching an Indian family business version of Succession 😅 Four listed companies. Three family branches. Cross-holdings everywhere. Court cases. Governance battles. And completely different business models. Meanwhile the stocks have all gone in different directions: • KOEL → market favourite 🚀 • KPCL → quiet compounder 📈 • KIL → hidden value play 💰 • KBL → governance debate ⚠️ So we decided to finally sit down and map the entire saga properly. Our latest proprietary deck covers: • Who controls what • The 2009 family settlement • Why the disputes started • Which businesses are actually strong • Where the valuation gaps are • And which Kirloskar company may offer the best setup today Honestly, one of the most fascinating Indian industrial group studies we’ve worked on. 138 years of history. 4 listed companies. 1 very complicated family tree. Full deck below: birchtree.ai/view-doc/do88df… #Kirloskar #IndianStocks #ValueInvesting #KOEL #KPCL #KBL #KIL
1
7
303
India’s logistics sector may be entering its most important transformation cycle in decades. Our latest AI enabled sector deep-dive maps how: • E-commerce • AI-driven routing • Gig logistics • SaaS freight platforms • Automation • Infrastructure buildout are reshaping a $230B industry. Key findings from the report: • India logistics market projected to scale from ~$230B to ~$545B by 2030 • E-commerce shipments could rise from ~5B to ~16B annually by FY30 • Structural shift toward tech-enabled 3PL platforms accelerating We analyze four distinct models shaping the ecosystem: 1. Delhivery — integrated scale AI/logistics OS 2. Shadowfax — gig-native quick-commerce disruptor 3. Blue Dart — premium air express franchise 4. BlackBuck — asset-light trucking SaaS platform A few observations stood out: • Delhivery has crossed the profitability inflection with 1B parcels delivered in FY26 • Shadowfax has rapidly gained e-commerce market share through quick commerce reverse logistics • Blue Dart remains the premium reliability franchise, though margins are under pressure • BlackBuck may be building one of India’s strongest logistics SaaS models with FY26 turning into its first full profitable year The broader takeaway: Indian logistics is evolving from a fragmented transportation industry into a technology network-effects business. The winners may increasingly be determined by: • Route density • AI optimization • Data ownership • Platform stickiness • Ecosystem integration rather than fleet ownership alone. birchtree.ai/view-doc/872qdz… #Logistics #IndianStocks #Delhivery #BlackBuck #BlueDart #Shadowfax #Ecommerce #AI #SupplyChain #India
10
4,601
Most investors are looking at AI data centers. Very few are looking at the companies that actually electrify them. Our latest deep-dive is on Vivid Electromech ($VIVIDEL) — a newly listed SME player sitting at the intersection of: • AI/GPU data centers • Metro rail • Power infrastructure Thread 🧵 1/ The core thesis is simple: A data center cannot go live without electrical panels, switchgear integration, protection systems, synchronization panels, UPS distribution and SCADA integration. Very few companies in India are authorized to build these systems. 2/ Vivid is one of the few Indian system integrators with: • ABB ArTu K authorization • In-house CNC robotic manufacturing • 35 year OEM relationships • Strong exposure to data centers This creates a scarcity moat. 3/ The market may still be underestimating the GPU transition. GPU data centers are NOT just bigger CPU data centers. They require: • Higher power density • 2N redundancy • More switchgear • More UPS distribution • CDU cooling control systems • Higher-value electrical architecture Meaning: materially higher revenue per MW. 4/ Our analysis suggests: 100 MW CPU DC panel opportunity ≈ ₹15 Cr 100 MW GPU DC panel opportunity ≈ ₹49 Cr ~3.2× increase in SI revenue opportunity for the same IT capacity. 5/ And India’s announced AI/DC pipeline is becoming enormous: • Reliance AI infra • Microsoft expansion • Yotta GPU hubs • TCS DC infra • L&T NVIDIA sovereign AI factory This is before the full hyperscaler build cycle begins. 6/ FY26 numbers already look strong: • Revenue: ₹200 Cr ( 28.8%) • PAT: ₹31.6 Cr ( 56.5%) • PBT margin: 21.8% Importantly — these are PRE-GPU and PRE-expansion numbers. 7/ Ambernath expansion funded by IPO proceeds could become the next major trigger: • Capacity step-up ahead • GPU DC construction cycle likely FY27 • Metro rail pipeline still expanding Management is effectively scaling before demand fully hits. 8/ Key risks remain: • Rising debtor days • Customer concentration • Execution on expansion • SME liquidity/track record But structurally, the sector backdrop may be one of the strongest in Indian infra manufacturing today. 9/ Our proprietary framework score: ACCUMULATE — 7.1/10 Sector dynamics received one of the highest scores in our coverage universe. 10/ Our internal note- birchtree.ai/view/9jw6lzfd3m… #VIVIDEL #AI #DataCenters #IndianStocks #StockMarketIndia #Infra #Semiconductors #PowerInfrastructure #Smallcaps
1
5
14
1,714
Carborundum Universal (CUMI) — one of India’s most interesting industrial compounders — may be entering a major transition phase. Our latest proprietary deep-dive covers: • India business acceleration • Russia/VAW overhang • Semiconductor optionality • Ceramics expansion • FY27–FY29 scenarios Key takeaways 🧵 1/ FY26 consolidated numbers look weak on the surface: • Revenue: ₹5,149 Cr ( 6.5%) • PAT: ₹196 Cr • EBITDA margin compressed to ~11% But headline numbers hide the real story. 2/ India standalone business is VERY strong: • Q4 standalone revenue 26% • FY26 standalone PAT: ₹416 Cr • Ceramics 21.7% • Electrominerals 22.3% Core India manufacturing cycle is clearly improving. 3/ Biggest drag remains VAW Russia: • OFAC sanctions continue • ₹297 Cr restricted cash locked • Export business impacted heavily This single factor is distorting consolidated earnings. 4/ Meanwhile, management is quietly building long-duration optionalities: • Semiconductor ceramics • Aerospace & defence ceramics • High-purity silicon carbide • SOFC ceramics for AI/data centres FY27 serial production for semiconductor components begins. 5/ Hosur ceramics capacity doubling may become a major FY27 earnings trigger. Ceramics already operate at ~24-25% EBIT margins — highest in the portfolio. 6/ Our framework suggests: • Strong India moat (>30% abrasives share) • Structurally attractive industrial positioning • Near-term earnings distortion from overseas assets • Valuation still demanding Composite framework verdict: NEUTRAL (6.7/10). 7/ The BIG variable: If Russia sanctions eventually ease, CUMI’s earnings power could rerate sharply through VAW normalization alone. Potential PAT swing is significant. 8/ We also map: • Bear / Base / Bull FY27–FY29 scenarios • Margin recovery pathways • Technical structure • Risk matrix • Peer comparison • Management guidance tracker Proprietary report below, not investment advice: birchtree.ai/view/km9csdbyix… #CUMI #CARBORUNIV #IndianStocks #Investing #StockMarketIndia #Manufacturing #Smallcaps #Semiconductors #Defence #IndustrialStocks

5
411
India’s Pharma CDMO story is entering a new phase. Our proprietary sector research compares four very different plays across the value chain: • Sai Life Sciences — pure-play CRDMO • Laurus Labs — scale CDMO pivot • Neuland Laboratories — complex chemistry peptides • Solara Active Pharma Sciences — turnaround/API restructuring Key takeaways from FY26: • Sai Life PAT 109% • Laurus PAT 148% • Neuland Q4 EBITDA margin at 40.5% • Solara posts strongest quarter in 8 quarters Bigger picture: India CDMO is scaling faster than global peers, supported by BIOSECURE tailwinds, China 1 sourcing shifts, and cost/regulatory advantages. Four companies. Four different models. One structural opportunity. birchtree.ai/view-doc/jhdukd… #Pharma #CDMO #CRDMO #India #Healthcare #Biotech #Investing #Equities #API #LifeSciences
1
2
20
1,468
Excellent presentation on Sasken.
Just released on Latticework: Sasken: From Project-Based Services to a Silicon Royalty Flywheel - Presentation at Asian Investing Summit 2026 latticework.com/p/sasken-fro…
1
10
472
More than the results future roadmap will drive the perception as well as change in multiples, short video- birchtree.ai/view-doc/hiydrt…
Intellect Designs good results and more importantly a great future guidance, rare Indian AI platform play- birchtree.ai/view-doc/3gntbj… #IntellectDesign
7
332
Intellect Designs good results and more importantly a great future guidance, rare Indian AI platform play- birchtree.ai/view-doc/3gntbj… #IntellectDesign
2
10
742